The study of cross-resistance of MTB to certain anti-tuberculosis drugs among tuberculosis patients in Tomsk Region

The objective of the study: to assess the prevalence of drug resistance of tuberculous mycobacteria (MTB) to pyrazinamide, linezolid, cross-resistance to fluoroquinolones, and cross-resistance to injectable anti-tuberculosis drugs among tuberculosis patients in Tomsk Region.

Subjects and methods. The data of 814 patients with tuberculosis were analyzed. Of them, drug susceptibility test to pyrazinamide was performed in 812 patients; ofloxacin, levofloxacin, moxifloxacin – in 475 patients; kanamycin, amikacin, capreomycin – in 301 patients, and linezolid – in 423 patients.

Results. The frequency of resistance to pyrazinamide is the highest in patients who were treated with pyrazinamide in the past (relapses and chronic cases). In the patients resistant to ofloxacin, the frequency of susceptibility to levofloxacin is low (16.9%), while susceptibility to moxifloxacin is higher (41.3%). The cross-resistance of MTB to kanamycin and amikacin makes less than 50% in the cases resistant to one of these two drugs. 38.6% of patients with poly-resistance to kanamycin and capreomycin, remain sensitive to amikacin. The level of MTB resistance to linezolid was minimal – 2.8% of those examined.

1. Set protivotuberkuleznykh meditsinskikh organizatsiy v Rossii v 2016 g. (analiticheskiy obzor). [The network of medical TB units in Russia in 2016. (analytic review)]. Moscow, TSNIIOIZ Publ., 2017, 56 p.

2. Epidemicheskaya situatsiya po tuberkulezu v Rossii v 2016 g. (analiticheskiy obzor). [Tuberculosis epidemiological situation in Russia in 2016 (analytic review)]. Moscow, TSNIIOIZ Publ., 2017, 69 p.

3. Chuang P.H., Wu M.H., Fan S.Y., Lin K.Y. Population-based drug resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007-2014. PLoS One, 2016, 11, no. 11, pp. e0165222.

4. Du Q., Dai G., Long Q., Yu X., Dong L., Huang H., Xie J. Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China. Diagn. Microbiol. Infect. Dis., 2013, vol. 77, no. 2, pp. 138-142.

5. Jugheli L., Bzekalava N., de Rijk P., Fissette K., Portaels F., Rigouts L. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob. Agents Chemother., 2009, vol. 53, no. 12, pp. 5064-5068.

6. Krüüner A., Jureen P., Levina K., Ghebremichael S., Hoffner S. Discordant Resistance to Kanamycin and Amikacin in Drug-Resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2003, vol. 47, no. 9, pp. 2971-2973.

7. Pang Y., Zhu D., Zheng H., Shen J., Hu Y., Liu .J, Zhao Y. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect. Dis., 2017, no. 17, pp. 711.

8. Zignol M., Dean A.S., Alikhanova N., Andres S., Cabibbe A.M. et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect. Dis., 2016, vol. 16, no. 10, pp. 1185-1192.